DNA Molecular Markers: Evolutionary Dynamics, High-Throughput Discovery, and Strategic Application in Genomic Research

Meta intent: A strategic, research-focused guide to selecting DNA molecular marker systems for diversity analysis, mapping, GWAS, phylogenomics, and breeding workflows.

DNA molecular markers changed genomics by turning sequence variation into something measurable. Early systems detected variation indirectly, through fragment size or banding patterns. Modern systems increasingly resolve alleles at defined loci and convert variation into portable digital genotypes. That shift changed more than throughput. It changed how researchers design projects, compare datasets, and move from broad discovery to downstream validation.

This overview is intended for research use and genomic workflow planning only, with emphasis on marker selection, assay design, and downstream data strategy.

The most useful question is no longer which marker systems exist. The real question is which system fits the biological endpoint. A panel that works well for diversity analysis may be too sparse for fine mapping. A reduced-representation sequencing workflow that is excellent for SNP discovery may be inefficient for routine downstream genotyping. A marker with high generic polymorphism may still fail in breeding if it does not track the target locus reliably in the real germplasm under selection. For that reason, DNA markers are best understood not as a historical list, but as a fit-for-purpose strategy.

Figure 1. Marker evolution reflects not only higher throughput, but also a shift from fragment-pattern readouts to portable, sequence-defined genotype calls.

The spectrum of marker systems

One practical way to classify marker systems is by what they detect. Older platforms often detect differences in fragment length after digestion or amplification. Newer platforms increasingly detect specific sequence states at defined genomic positions. That distinction shapes almost everything downstream: allele interpretation, reproducibility, cross-lab portability, and compatibility with modern statistical workflows for diversity analysis, mapping, or association studies.

From RFLP and AFLP to SSR and SNP

Restriction fragment length polymorphism, or RFLP, was one of the earliest robust DNA marker systems. It relies on restriction digestion followed by fragment separation and locus-specific detection. Sequence changes that create or abolish restriction sites, or alter fragment length, produce different patterns. RFLP was historically important because it was locus-aware and reproducible, but it was also slow, labor-intensive, and difficult to scale. That limited its long-term value in large cohort studies.

AFLP kept the logic of restriction digestion but increased multiplex output. It became useful for fingerprinting and diversity work because many polymorphic fragments could be generated in a single assay. The trade-off was interpretability. Fragment presence and absence can be informative, but they do not always preserve full genotype resolution. As sequencing-based systems matured, AFLP became less attractive in projects that required portable, locus-defined genotypes.

SSRs, or microsatellites, marked a major step forward because they are codominant and often highly polymorphic. Instead of scoring a broad fragment pattern, researchers could compare alleles at defined repeat loci and distinguish homozygous from heterozygous states directly. For years, SSRs were the workhorse of population genetics, parentage analysis, linkage mapping, and germplasm evaluation. Their value remains clear today. They often provide high per-locus information content, and their multi-allelic nature can be especially useful in diversity-focused projects.

SNPs shifted the field into a different operating mode. Most SNP loci are only bi-allelic, so each individual locus is usually less polymorphic than a typical SSR. But SNPs are abundant, broadly distributed, and highly compatible with array- and sequencing-based genotyping. Once large numbers of SNPs could be scored cheaply and reproducibly, marker analysis moved away from maximizing the information content of one locus and toward integrating information across thousands of loci at genome scale. That is one reason SNP-centered strategies now dominate high-throughput genomic research.

Why codominant markers matter more than dominant markers

The difference between dominant and codominant markers is not a minor technical detail. It determines how much biological information survives the assay.

A dominant marker usually collapses genotype states into presence or absence. In diploids, that means a heterozygote can become indistinguishable from one class of homozygote. Once that happens, heterozygosity estimates, allele-frequency inference, and population-structure analysis all become less direct and often less reliable.

A codominant marker preserves both allelic states at a locus. SSRs usually do this through fragment-length differences. SNPs do it through sequence-defined alleles. The result is cleaner genotype resolution and stronger compatibility with modern statistical analysis.

This is why codominant markers are usually preferred in diversity analysis, kinship estimation, admixture analysis, and most mapping workflows. They do not just produce neater data. They preserve the genotype classes needed to measure heterozygosity and model segregation properly. In practice, codominance reduces information loss at the exact point where biological interpretation begins.

Figure 2. Dominant assays compress heterozygous and homozygous states, whereas codominant markers preserve genotype resolution for allele-frequency analysis, heterozygosity estimation, and population structure.

PIC and heterozygosity are related, but not interchangeable

Two terms appear constantly in marker evaluation: heterozygosity and polymorphism information content, or PIC. They are related, but they are not the same metric.

Expected heterozygosity describes the probability that sampled alleles differ at a locus. It is a diversity measure driven by allele frequencies within the target cohort. PIC also depends on allele frequencies, but it focuses more directly on how informative the marker is for distinguishing polymorphism in that population. For balanced allele distributions, both values tend to rise. For strongly skewed allele distributions, both tend to fall.

This has two important implications. First, marker quality is cohort-specific. The same marker can be highly informative in one population and weak in another. Second, strong generic polymorphism does not automatically make a marker useful for every project. A marker may show high PIC in a diversity panel yet still perform poorly in breeding if it is weakly linked to the target region or behaves inconsistently across breeding lines.

For discovery work, broad informativeness matters. For downstream validation, linkage quality and assay robustness often matter more. That is why PIC should be treated as a useful indicator, not as a universal score that answers every marker-selection question by itself.

Figure 3. PIC and heterozygosity both depend on allele-frequency distribution, but PIC is specifically used to evaluate marker informativeness within the target cohort.

Technical sovereignty in the NGS era

Next-generation sequencing changed marker discovery by allowing researchers to discover and score variation within the same experimental framework. Once sequencing output became scalable, the limiting question was no longer whether polymorphism could be detected. The real question became which fraction of the genome should be sampled, how reproducibly it could be sampled across individuals, and whether the resulting marker set would match the downstream goal.

Reduced-representation sequencing methods emerged from that problem. Instead of sequencing every base, they intentionally recover reproducible genomic subsets that are rich enough for SNP discovery and genotyping. GBS, RAD-seq, and DArTseq all belong to this broad logic, but they solve the problem in different ways.

GBS: high-throughput SNP discovery by controlled complexity reduction

Genotyping-by-sequencing is often described as a low-cost SNP method, but that label is too shallow. GBS works because it uses restriction enzymes to transform a full genome into a reproducible reduced library. Genomic DNA is digested, adapters and barcodes are ligated, fragments are pooled, and the library is sequenced in multiplex. Homologous fragments recovered across individuals can then be aligned and compared for SNP discovery and genotype calling.

The strength of GBS lies in controlled complexity reduction. The method does not try to treat every part of the genome equally. It samples the genome strategically. That is why restriction enzyme choice is not a small protocol setting. It is one of the main determinants of data quality.

Recognition-site frequency affects how many fragments enter the library. Methylation sensitivity affects whether repetitive, often less informative genomic regions are overrepresented or suppressed. Genome size and repeat load determine how much of the resulting library will be analytically useful. A cutter that performs well in a compact genome may create overwhelming complexity in a large, repeat-rich genome. The downstream symptoms are familiar: shallow per-locus depth, uneven locus recovery, inflated missing data, and heavier filtering.

Multiplexing adds another layer of trade-off. Pooling many samples is one reason GBS is cost-effective, but cost per sample drops only as long as sequencing depth remains adequate for the study design. Low depth can be acceptable in some population-scale surveys, especially when marker density is high and imputation is feasible. It becomes much riskier when individual genotype certainty matters, when the reference genome is weak, or when the population structure makes imputation unstable. Cheap data are not always economical data.

The strongest use case for GBS is early-stage genomic discovery at scale. It is highly effective for broad SNP discovery, dense linkage mapping, germplasm screening, and exploratory genotype-phenotype work in cohorts too large for routine whole-genome resequencing. It is often a strong fit when projects need many markers across many samples and can tolerate analytical filtering.

In that context, Genotyping by Sequencing (GBS) is naturally aligned with discovery-driven projects, while Whole Genome SNP Genotyping is often more suitable when broader SNP matrices are needed across large sample sets.

Figure 4. GBS reduces genome complexity through restriction digestion and multiplexed library construction, but marker yield and missingness depend strongly on enzyme choice, sequencing depth, and genome architecture.

Why GBS projects fail when the design logic is weak

Many summaries explain the GBS workflow but stop before the real problem. Why do some GBS datasets underperform?

The first reason is inconsistent fragment recovery. If DNA quality varies, digestion efficiency shifts, or library preparation introduces bias, the same loci may not be recovered evenly across samples. The second reason is insufficient depth. If too many fragments compete for too few reads, genotype confidence drops. The third reason is poor reference support. If the available reference genome is fragmented, distant, or incomplete, alignment quality suffers and locus interpretation becomes less stable. The fourth reason is over-filtering after weak experimental design. A project may begin with many candidate loci but lose a large fraction once missingness, depth, and reproducibility thresholds are applied.

These are not arguments against GBS. They are reminders that GBS is a design-sensitive platform. The best GBS projects are not built from protocol habit. They are built backward from the research endpoint.

RAD-seq: stronger locus context, but more protocol-dependent trade-offs

RAD-seq belongs to the same reduced-representation family as GBS, but it should not be treated as interchangeable. Its core logic is to recover and sequence DNA adjacent to restriction sites, which gives researchers a reproducible set of flanking loci for SNP discovery and genotyping. That structure made RAD-seq especially influential in ecological genomics, recent phylogenetic radiations, population divergence studies, and fine mapping in non-model organisms.

The value of RAD-seq is not only marker number. It is the combination of broad genomic sampling with local sequence context. In the right setting, that makes it attractive for clade-scale phylogenomics and focused mapping work. But RAD-seq is highly sensitive to protocol architecture. Restriction-site dropout can reduce locus recovery across divergent taxa. Size-selection choices can alter locus overlap among individuals. Library-to-library inconsistency can amplify missing data. As evolutionary distance grows, shared restriction sites may disappear, and locus comparability declines.

Those are not reasons to avoid RAD-seq. They are reasons to treat it as a carefully tuned design family rather than a plug-and-play assay. In practical terms, GBS often wins on scalable cohort screening, while RAD-seq may be better aligned with applications where locus architecture, recent divergence, or flanking-site recovery matters more.

In projects that need this style of reduced-representation genotyping, ddRAD-seq can be a more structured choice when tighter control over library architecture is important.

DArTseq: efficient marker generation in reference-light systems

DArTseq occupies a different strategic niche from both GBS and RAD-seq. It also relies on genome complexity reduction, but its strongest appeal is practical efficiency in species where genomic infrastructure is still limited. In systems with incomplete reference genomes, fragmented assemblies, or poorly characterized diversity panels, researchers often need a platform that can generate informative genome-wide markers before a mature SNP ecosystem is in place.

That is where DArTseq becomes useful. Its value is not just that it produces many markers. Its value is that it lowers the entry barrier to broad genomic screening. For orphan crops, under-characterized breeding populations, or non-model organisms, that can be the difference between a stalled project and a workable first-pass dataset. In projects that are not yet ready for fully standardized genome-wide SNP resources, broad discovery routes such as Whole Genome SNP Genotyping or reduced-representation workflows can help establish the first useful map of genomic variation.

Still, DArTseq should not be treated as a universal endpoint. Marker generation can be efficient, but downstream assay conversion is not always as direct as it is in workflows built around explicitly resolved SNP loci from the start. This is the real strategic trade-off. DArTseq can be very strong for early profiling, diversity screening, and broad comparative analysis, but once a project starts asking for tighter interval resolution, assay conversion, or more standardized locus-specific interpretation, researchers often need to move toward a narrower downstream format.

That is why DArTseq is best viewed as a front-end discovery tool in reference-light systems. It helps projects get moving. It does not always solve the last mile of marker deployment.

How to choose the right marker system

Choosing a marker platform becomes much easier once the input variables are defined clearly. Many teams make the decision too early. They start with platform names instead of project structure. A better approach is to define the biology first, the data architecture second, and the technology third.

The most important variables are genome size, ploidy, reference quality, sample count, target marker density, tolerance for missing data, and the true endpoint of the study. That last variable is usually the one that prevents costly mistakes. A project designed for broad discovery should not be forced prematurely into a routine genotyping format. A project that ultimately needs a repeatable breeding assay should not assume that the discovery platform will remain the final platform.

Genome size shapes complexity. Small diploid genomes with modest repeat content are much more forgiving in reduced-representation workflows. Large, repeat-rich genomes are not. The same restriction strategy that behaves cleanly in one species may generate excessive complexity in another. When the goal is to generate a large first-pass SNP matrix across many samples, Genotyping by Sequencing (GBS) can be a strong fit, but only when enzyme logic, genome composition, and sequencing depth have been matched properly.

Ploidy complicates the picture further. Polyploid systems make allele dosage and genotype calling harder, especially when locus definition is weak or read depth is uneven. In those settings, researchers often need stronger validation after discovery. That is one reason broad discovery may begin with ddRAD-seq or GBS, but the project later shifts toward narrower validation formats once the biologically useful loci are known.

Reference quality matters just as much. Strong references improve read alignment, locus annotation, SNP interpretation, and downstream transferability. Weak references do not make marker projects impossible, but they do change the logic of platform choice. In reference-light systems, reduced-representation sequencing may be the right first move. In reference-rich systems, broader variant pipelines such as Variant Calling become much more powerful because the project can move more confidently from raw reads to locus-level interpretation.

Sample count changes the economics. A small project can sometimes tolerate more labor per sample if the biological question is precise. Large cohort studies reward scalability. That is why researchers handling hundreds of samples often move toward platforms that compress cost per sample without giving up too much informative density. In those situations, Whole Genome SNP Genotyping or GBS-style workflows often become attractive because they support broader comparisons across large populations.

Marker density need is another dividing line. If the study only requires moderate discrimination among accessions, SSRs may still be enough. If the project depends on interval narrowing, LD coverage, or genome-wide association logic, dense SNP-centered platforms become much more appropriate. Once that transition happens, the workflow often expands beyond genotyping alone and begins to connect with population-level interpretation through services such as Genome-wide Association Study (GWAS).

Tolerance for missing data is the variable that many teams define too late. Some projects can absorb moderate missingness. Others cannot. If the goal is broad exploratory discovery, some missing data may be manageable. If the goal is fine mapping or targeted downstream validation, inconsistent locus recovery becomes much more damaging. In those cases, the project often benefits from moving out of broad discovery and into region-focused validation through SNP Fine Mapping or narrower locus-specific assays.

A quick decision framework

The central rule is simple: discovery and deployment are different problems. A platform that is excellent for genome-wide discovery may still be the wrong choice for the final validated assay. Many strong projects therefore use a staged path rather than a single permanent platform.

Matching marker systems to research goals

Diversity analysis and population structure

Diversity analysis depends on codominance, allele-frequency resolution, and enough informative loci to separate real structure from sampling noise. This is why marker choice must start with the analytical question, not with platform popularity.

SSRs still perform well in many diversity studies because they combine codominance with strong per-locus variability. In smaller or medium-sized projects, especially where multi-allelic information is valuable, SSRs remain highly practical. When the project needs broader locus coverage across larger sample sets, however, SNP-centered workflows become more attractive. Researchers moving in that direction often start with Whole Genome SNP Genotyping when they need large marker matrices across accessions, populations, or breeding panels.

The practical shift is not from "old markers" to "new markers." It is from high information per locus to high breadth per project. That is the real decision.

Phylogenetics and phylogenomics

Phylogenetic marker choice depends strongly on evolutionary depth. Very recent divergence benefits from dense and locally comparable genomic windows. Reduced-representation sequencing is often useful here because it can generate large marker sets without the cost of full resequencing.

RAD-seq is often attractive in shallow-to-intermediate divergence settings, such as recent radiations, population splits, and clade-scale phylogenomics. Its advantage is breadth with local sequence context. But that advantage weakens as taxa become more divergent. Restriction-site loss accumulates over time. Once homologous restriction-associated loci stop being shared reliably across lineages, locus overlap declines and comparability becomes harder to maintain.

This is why projects focused on recent divergence, clade-scale structure, or species-complex resolution often prefer ddRAD-seq over a more generic discovery workflow. The tighter control over fragment architecture can be especially valuable when the real challenge is not simply finding markers, but finding markers that remain comparable across the exact taxa being analyzed.

Linkage mapping and fine mapping

Mapping changes the balance again because density directly affects resolution. Sparse markers can show that a region matters, but dense markers are needed to narrow that region effectively. This is one of the strongest domains for GBS and RAD-seq. Both can place many markers across the genome and increase the chance that informative loci sit near recombination breakpoints and trait-associated intervals.

In early-stage mapping, Genotyping by Sequencing (GBS) is often a practical choice because it supports broad marker discovery across many individuals at manageable cost. But once the interval starts to narrow, the project usually changes character. Breadth becomes less important than regional confidence. That is the point where SNP Fine Mapping becomes much more relevant, because the goal is no longer to scatter markers broadly across the genome. The goal is to refine the biologically meaningful interval with tighter regional focus.

This staged shift is where many resource pages stay too general. In real projects, mapping success depends not only on dense discovery, but on knowing when to stop expanding marker breadth and start intensifying local resolution.

GWAS

GWAS imposes a different set of demands because the analysis depends on linkage disequilibrium structure, marker density, population composition, and cross-sample comparability. The platform choice is therefore not just about price. It is about whether the marker set captures the LD structure that actually exists in the target population.

If a species already has a mature SNP ecosystem, arrays or validated SNP panels may provide stronger cross-study comparability. That is especially important when standardization matters across breeding programs, research centers, or historical datasets. But established panels are not automatically neutral. If they were built from a narrow discovery population, ascertainment bias can distort representation in broader or more diverse germplasm.

GBS offers a more flexible alternative when SNP resources are sparse or when the project still needs discovery. But flexibility comes with design sensitivity. Library structure, missingness, depth, and locus filtering all shape the final dataset. This is why GWAS is not just a statistical layer added after sequencing. It is part of the original platform decision.

In practice, many GWAS-oriented projects combine a genotyping route with downstream analytical support. A dataset generated through Whole Genome SNP Genotyping or GBS becomes much more useful once it is paired with robust Variant Calling and a defined Genome-wide Association Study (GWAS) workflow. The value is not just in generating markers. It is in translating those markers into an interpretable association-ready matrix.

Marker-assisted selection

Marker-assisted selection is where the difference between discovery and deployment becomes most obvious. A discovery marker only needs to reveal useful variation. A breeding marker has to do much more. It must track the relevant region reliably, behave consistently across the real breeding material, produce low error rates, and remain practical enough for repeated routine use.

This is why strong generic polymorphism is often overrated in breeding. A marker can be highly polymorphic and still be weak for selection if it is only loosely linked to the real target. Strong generic informativeness does not guarantee strong predictive value for the locus that matters in the breeding workflow.

This is also why dense discovery datasets are rarely the end of the story. A project may begin with Genotyping by Sequencing (GBS) or ddRAD-seq to identify candidate regions. It may then move into SNP Fine Mapping to sharpen the interval. Once the locus set is sufficiently clear, the project often needs a narrower validation route. At that stage, Amplicon Sequencing Services can be useful for focused locus confirmation, while TaqMan SNP Genotyping or MassARRAY SNP Genotyping may be better suited for repeatable targeted genotyping in a routine screening workflow.

That progression matters because MAS is not won by the platform with the most markers. It is won by the platform that keeps the right markers stable at the point where real selection decisions are made.

A practical comparison of major marker systems

No one platform wins every category. RFLP is reproducible but low-throughput. SSRs are highly informative per locus but not naturally genome-wide. SNP arrays are standardized but depend on prior marker ecosystems. GBS and RAD-seq are strong discovery engines, but they require design discipline and often later conversion. DArTseq is efficient in reference-light systems, but it is not always the clearest bridge to tightly targeted downstream assays.

That is why comparison tables are only useful when they lead to workflow decisions. Once a project needs to move from broad discovery into narrower validation, researchers often stop asking which platform is "best" and start asking which platform is best now. In that transition, tools like Variant Calling, SNP Fine Mapping, and targeted genotyping formats become far more important than raw discovery density alone.

A staged workflow: discovery first, deployment second

Many marker projects become inefficient because they try to force one platform to solve every stage of the workflow. A better strategy is staged.

Stage 1: broad genomic discovery.
The goal here is to find variation, describe structure, or localize genomic intervals. High-density approaches such as Genotyping by Sequencing (GBS), ddRAD-seq, or Whole Genome SNP Genotyping are often strongest at this stage.

Stage 2: locus narrowing and validation.
Once informative regions are identified, the project shifts from breadth to confidence. The question becomes which loci remain robust after filtering, validation, and testing across relevant materials. This is where SNP Fine Mapping and focused Amplicon Sequencing Services start to play a much larger role.

Stage 3: targeted routine genotyping.
At this point, the winning platform often changes again. A small number of well-performing markers can now be moved into cleaner, narrower, and more repeatable assay formats such as TaqMan SNP Genotyping or MassARRAY SNP Genotyping.

This three-stage logic is often what separates a research-grade marker discovery exercise from a usable marker workflow. The discovery platform does not need to be permanent. It only needs to perform well enough to identify the right loci for the next phase.

From marker abundance to fit-for-purpose marker strategy

DNA molecular markers did not evolve toward one perfect platform. They evolved toward different balances of density, informativeness, reproducibility, and deployability.

RFLP and AFLP established the principle that DNA variation could be tracked systematically. SSRs increased allelic resolution and remain valuable where multi-allelic information matters. SNP-centered systems transformed genotyping into a scalable digital framework. GBS, RAD-seq, and DArTseq extended that framework by making high-throughput discovery practical in settings where whole-genome resequencing would be excessive, inefficient, or too expensive.

The most useful marker strategy is therefore the one that fits the endpoint. For diversity analysis, codominance and interpretable allele frequencies matter most. For mapping and GWAS, genomic breadth and marker density become more important. For phylogenomics, locus recoverability across taxa becomes a defining constraint. For breeding, robust downstream genotyping often matters more than maximum marker abundance.

Once that logic is made explicit, marker selection becomes less about platform fashion and more about experimental alignment. Researchers no longer need only more markers. They need marker systems that preserve the right information, at the right scale, for the next real step in the workflow. In practice, that often means connecting discovery-oriented platforms with downstream services such as Variant Calling, SNP Fine Mapping, and targeted assay formats rather than expecting one broad platform to carry the entire project alone.

Figure 5. GBS, RAD-seq, and DArTseq share a reduced-representation logic, but differ in fragment recovery architecture, locus transparency, and downstream best-fit applications.

Figure 6. Marker selection should begin with the biological endpoint, then work backward through genome complexity, reference quality, marker density needs, missing-data tolerance, and downstream assay format.

FAQ

What is the biggest difference between classical markers and modern sequencing-based markers?
Classical markers often rely on fragment-pattern readouts, while modern systems increasingly produce sequence-defined genotypes that are easier to scale, compare, and integrate into genome-wide analysis.

Why are codominant markers usually preferred for diversity analysis?
Because they preserve full genotype classes and support stronger estimates of allele frequency, heterozygosity, kinship, and population structure.

How much missing data is acceptable in a GBS project?
There is no universal threshold. Acceptable missingness depends on sequencing depth, population structure, locus recovery consistency, imputation strategy, and the real endpoint of the project. Exploratory diversity surveys can tolerate more missingness than fine mapping or targeted downstream validation.

When should I choose GBS instead of RAD-seq?
GBS is often preferred when scalable, economical SNP discovery across many samples is the main goal. RAD-seq is often a better fit when locus architecture, flanking-site recovery, or recent-divergence phylogenomics matters more.

Is DArTseq a good option without a reference genome?
Often yes. DArTseq can be especially useful in non-model or reference-light systems where researchers need broad marker generation before a mature genomic infrastructure exists.

Are SSRs obsolete now that SNP methods dominate?
No. SSRs still perform well in parentage analysis, diversity studies, and projects where high multi-allelic information per locus is more valuable than maximum marker density.

What determines whether a discovery marker can be converted into a routine breeding assay?
The main factors are linkage quality, locus specificity, reproducibility, transferability across the target germplasm, and low error rates in the actual screening workflow.

Why are generic polymorphic markers sometimes weak for marker-assisted selection?
Because strong generic polymorphism does not guarantee strong predictive value for the target trait region. Trait-specific, validated markers usually perform better in breeding workflows than broadly informative but weakly linked markers.

References

1. Andrews KR, Good JM, Miller MR, Luikart G, Hohenlohe PA. Harnessing the power of RADseq for ecological and evolutionary genomics. Nature Reviews Genetics. 2016;17(2):81-92. DOI: 10.1038/nrg.2015.28
2. Botstein D, White RL, Skolnick M, Davis RW. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. American Journal of Human Genetics. 1980;32(3):314-331.
3. Elshire RJ, Glaubitz JC, Sun Q, Poland JA, Kawamoto K, Buckler ES, Mitchell SE. A robust, simple genotyping-by-sequencing (GBS) approach for high diversity species. PLoS ONE. 2011;6(5):e19379. DOI: 10.1371/journal.pone.0019379
4. Platten JD, Cobb JN, Zantua RE. Criteria for evaluating molecular markers: Comprehensive quality metrics to improve marker-assisted selection. PLoS ONE. 2019;14(1):e0210529. DOI: 10.1371/journal.pone.0210529
5. Semagn K, Babu R, Hearne S, Olsen M. Single nucleotide polymorphism genotyping using Kompetitive Allele Specific PCR (KASP): overview of the technology and its application in crop improvement. Molecular Breeding. 2014;33(1):1-14. DOI: 10.1007/s11032-013-9917-x
6. Serrote CML, Reiniger LRS, Silva KB, dos Santos Rabaiolli SM, Stefanel CM. Determining the polymorphism information content of a molecular marker. Gene. 2020;726:144175. DOI: 10.1016/j.gene.2019.144175
7. Kilian A, Wenzl P, Huttner E, Carling J, Xia L, Blois H, Caig V, Heller-Uszynska K, Jaccoud D, Hopper C, et al. Diversity Arrays Technology: A Generic Genome Profiling Technology on Open Platforms. In: Methods in Molecular Biology. 2012;888:67-89. DOI: 10.1007/978-1-61779-870-2_5
8. Li X, Hu Z, Yu W, Xie H, Wang X, Huang P, Zhang X, Yang J, Li Y, Zhao W, et al. Advances and challenges in plant molecular marker technologies and their applications in the artificial intelligence empowered era. Frontiers in Plant Science. 2026;16:1757949. DOI: 10.3389/fpls.2025.1757949
9. Yadav HK, Solanki RS, Kumar P. Recent advancements in molecular marker-assisted selection and applications in plant breeding programmes. Journal of Genetic Engineering and Biotechnology. 2021;19:128. DOI: 10.1186/s43141-021-00231-1
10. Gupta PK, Rustgi S, Kulwal PL. Linkage disequilibrium and association studies in higher plants: present status and future prospects. Plant Molecular Biology. 2005;57(4):461-485. DOI: 10.1007/s11103-005-0257-z

For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.